Oncoclinicas stock faces a board overhaul request
Published on 09/30/2026 at 18:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Oncoclinicas stock faces a board overhaul request from UBS Lumen, which holds 4.93 percent of the company's outstanding shares. Valor Economico reported on September 30, 2026, that the proposal is under review and must receive a response within eight days.
UBS Lumen seeks seven seats
The fund proposed a slate of seven candidates for the board, including Marcelo Curti, Helio Paulo Ferraz and Antonio Claudio Correa Leite Buchaul. The request adds a governance dispute to the financial pressure already surrounding the Brazilian oncology-care group.
The proposed meeting would consider removing the current board and electing a new composition. For investors, the key issue is whether the request changes oversight while the company manages debt and restructuring measures.
Debt weighs on second-quarter figures
In the second quarter of 2026, Oncoclinicas held BRL 112.0 million in cash and carried BRL 3.39 billion in financial debt, according to Eu Quero Investir. Accounting EBITDA was negative BRL 245.6 million, while the company reported a BRL 475.7 million loss for the quarter.
The figures show why governance and balance-sheet issues are moving together in the investment case. Debt stood at more than 30 times the quarter's cash balance, a comparison that highlights the limited liquidity cushion.
ONCO3 stays below its yearly high
ONCO3 was trading at BRL 1.02 on B3 at 1:23 p.m. BRT on September 30, 2026. The finance snapshot placed market capitalization at BRL 1.1 billion and the 52-week range at BRL 0.53 to BRL 3.91, leaving the stock 73.91 percent below the yearly high.
The next reported results are scheduled for November 5, 2026, according to Zonebourse. The next checkpoint combines operating performance with the board dispute and the company's ability to preserve cash.
Oncoclinicas at a glance
- Company: Oncoclinicas do Brasil Servicos Medicos S.A.
- Ticker: ONCO3
- Primary exchange: B3
- Market capitalization: BRL 1.1 billion (as of September 30, 2026)
- 52-week range: BRL 0.53-3.91 (as of September 30, 2026)
- Sector / Industry: Healthcare / Medical Care Facilities
- Next earnings date: November 5, 2026
